The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men - West of Scotland Coronary Prevention Study

James Sheperd, Stuart M. Cobbe*, Lorimer A. Ross, James H. McKillop, Ian Ford, Christoper J. Packard, Peter W. Macfarlane, Christopher Isles, Micheal F. Oliver, Anthony F. Lever, Byron W. Brown, John G G Ledingham, Stuart J. Pocock, Basil M. Rifkind, Barry D. Vallance, Ross A. Lorimer, James H. MsKillop, David Ballantyne, John Norrie, Liz AndersonDavid Duncan, Sharon Kean, Audrey Lawrence, June McGrath, Vivette Monthgomery, Melvyn Percy, Elspeth Pomphrey, Andrew Whitehouse, Patricia Cameron, Pamela Parker, Fiona Porteous, Leslie Flecher, Christine Kilday, David Shoat, Shahid Larif, Julie Kennedy, Margaret Anne Bell, Robert Birell, Margot Mellies, Joseph Meyer, Wendy Campbell

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


OBJECTIVES The purpose of the study was to assess the effect of lipid reduction with pravastatin on hospital admissions in middle-aged men with hypercholesterolemia in the West of Scotland Coronary Prevention Study.

BACKGROUND A prospective, randomized controlled trial was undertaken in primary care centers in the West of Scotland.

METHODS A total of 6,595 participants randomized to receive pravastatin 40 mg or placebo daily were followed up for a mean of 4.9 years (range 3.5 to 6.1 years). Analysis of hospital admissions was undertaken according to the "intention to treat" principle both for cardiovascular diseases and noncardiovascular diseases (including malignant neoplasms, psychiatric diagnoses, trauma and other causes). A secondary analysis of hospitalization in patients who were greater than or equal to 75% compliant was performed.

RESULTS During the trial, 2,198 (33%) of the 6,595 men were admitted to hospital on 4,333 occasions, of which 1,234 (28%) were for cardiovascular causes. Pravastatin reduced the number of subjects requiring hospital admission for cardiovascular causes by 21% (95% CI [confidence interval] 9 to 31, p = 0.0008) overall, and by 27% (95% CI 15 to 38) in compliant participants. The number of admissions per 1,000 subject-years for cardiovascular disease was reduced by 10.8 (95% CI 4 to 17.4, p = 0.0013) in all subjects, and by 15.6 (95% CI 8.3 to 23, p <0.0001) in compliant participants. Pravastatin had no significant influence on hospital admission for any noncardiovascular diagnostic category. There were 13.4 fewer admissions per 1,000 subject years for all causes in the pravastatin-treated group (95% CI -0.4 to 27.3, p = 0.076). No significant difference in duration of hospital stay was found between the pravastatin and placebo patients in any diagnostic group.

CONCLUSIONS Pravastatin therapy reduced the burden of hospital admissions for cardiovascular disease, without any adverse effect on noncardiovascular hospitalization. (J Am Coll Cardiol 1999;33:909-15) (C) 1999 by the American College of Cardiology.

Original languageEnglish
Pages (from-to)909-915
Number of pages7
JournalJournal of the American College of Cardiology
Issue number4
Publication statusPublished - 15 Mar 1999




Dive into the research topics of 'The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men - West of Scotland Coronary Prevention Study'. Together they form a unique fingerprint.

Cite this